Rijuven Corporation – Trademark Portfolio

Entity Type: 03

Rijuven Corporation holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include REJIVA, RIJUVEN, and CARDIOSLEEVE. The owner is based in Wexford, PA.

rijuven.com

10475 Perry Hwy., Suite 104

Wexford, PA 15090

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Rijuven Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (4 filings)

Surgical, medical, dental and veterinary apparatus and instruments

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Rijuven Corporation have?

Rijuven Corporation has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 1 cancelled.

What trademark classes does Rijuven Corporation file in?

Rijuven Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Rijuven Corporation's most well-known trademarks?

Rijuven Corporation's registered trademark portfolio includes well-known marks such as REJIVA, RIJUVEN, and CARDIOSLEEVE. These are among 3 currently registered trademarks in the portfolio.

What is Rijuven Corporation's trademark registration success rate?

Rijuven Corporation has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.